KR20210006089A - Pharmaceutical composition for preventing or treating vitiligo or canities comprising extract of Mangifera indica L. extract as an active ingredient - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating leukoplakia or canities containing an apple mango extract as an active component. The apple mango extract of the present invention has no cytotoxicity, promotes differentiation and migration of melanoblasts, and exhibits antioxidant activity, thereby being able to be usefully used for treating leukoplakia or canities.

Description

Pharmaceutical composition for preventing or treating vitiligo or canities comprising extract of Mangifera indica L. extract as an active ingredient, comprising apple mango extract as an active ingredient}

The present invention relates to a pharmaceutical composition for preventing or treating vitiligo or leukoplakia comprising an apple mango extract as an active ingredient.

The melanin pigment determines the skin color and absorbs ultraviolet rays to protect the skin. Melanocytes that produce melanin pigments are derived from melanoblasts. When melanoblast is stimulated to differentiate into melanocytes, tyrosinase is activated to change the tyrosine contained in the cell to DOPA (3,4-dihydroxy-L-phenyl-alanine), and then DOPA is dopaoxidase ( It is converted into a substance called dopaquinone by the action of an enzyme called dopaoxidase, and then synthesized into melanin through a series of chemical reactions. After making melanin, melanocytes move to the epidermal tissue in the upper layer of the skin, and deliver the melanin to keratinocytes present in the epidermal tissue. During the cell migration process, melanin pigment is stored and transported in melanosomes, but it has no color at the beginning of its production, and then gradually moves to the upper layer, filling with black pigment over 4-5 steps, and finally becoming fully pigmented mature melanin granules.

Vitiligo is an acquired depigmentation disease in which white spots of various sizes and shapes appear on the skin due to the death or necrosis of melanocytes. Vitiligo patients lost the activity of epidermal melanocytes, but melanoblast cells of the outer follicle sheath of the hair follicle were not affected. It is a relatively common disease that occurs in about 1% of the world's population, and does not differ by race or region. The age of onset is most common between 10 and 30 years of age, 95% of cases develop before 40 years of age, and 30% of patients have a family history. As a clinical manifestation of vitiligo, round or irregular white spots of various sizes appear, the degree of discoloration is not clear at first, but often becomes more pronounced over time, and the boundary with normal skin may not be clear, but normal skin color. It can appear darker and more distinct. In rare cases, it may cause itching, and white spots may appear on hairy areas, especially hair and eyebrows, where white hairs may grow. Vitiligo can occur anywhere on the skin, but especially in areas where bones protrude such as fingers, toes, knees, and elbows, around the mouth, around the nose, around the eyes, underarms, and inside the wrists. It can also come to the mucous membranes such as the lips or genitals, and it occurs particularly well in areas that are frequently hurt. The distribution of vitiligo is symmetrical, or according to nerves (Vitiligo Pathogenesis and Treatment, American Journal of Clinical Dermatology June 2001, Volume 2, Issue 3, pp. 167-181).

Vitiligo can be accompanied by pigmentation abnormalities in the iris and retina of the eye, in addition to simply appearing white spots on the skin, diabetes, pernicious anemia, hypothyroidism or hyperactivity, Down syndrome, biliary cirrhosis, gastric cancer, Adison's disease, alopecia areata. , It can be associated with autoimmune diseases such as lupus erythematosus. Although the cause of vitiligo has not been accurately identified yet, various theories have been suggested, such as autoimmune theory, stress, viral hypothesis, neuronal humoral hypothesis, and melanocyte self-destruction theory. In addition, various factors such as inherited cellular defects, genetic factors, apoptosis, and abnormal calcium metabolism have been suggested.

Mango is one of the top 30 major crops in the world, and is a perennial tropical fruit tree belonging to the mangifera of the Anacardiaceae family, and its scientific name is Mangifera indica L. Mangoes have been cultivated in India for 4,000 years and are considered valuable, and were introduced to Southeast Asia in the 4th-5th century BC by monks. It was spread to East Africa by the Portuguese in the 10th century, and was first planted in Barbados, the West Indies, in 1742. Then, in 1782, it was transmitted from the Dominican Republic to Jamaica and from the Philippines and West Indies through Mexico to the United States. Mango has been cultivated in India since BC, but the original species is unknown (2). Mango, called the queen of fruits, is a representative subtropical fruit that ranks fifth after oranges, bananas, grapes, and apples among the world's fruit tree production, and its demand is gradually increasing in various forms of consumption in Korea. In Korea, mango imports began in the Philippines for the first time in 1993, and the number of mangoes has increased rapidly since 2000. More than 1,000 tons have been imported since 2006, and the average import volume from 2007 to 2008 is 1,725 tons (imported 6,337 thousand US$), which is increasing every year.

Pink Irwin, one of the mango varieties in the market, is also called Apple mango, and it usually weighs about 300 to 500 g. Apple mango is characterized by excellent shape, scent, and juicy. In addition, the most distinctive feature is that the skin is very thin. It has high sugar content, no fiber in the flesh, and has a strong scent (Park JK, An KW, Ahn YS. 2010. Mango. Chonnam National University Press, Gwangju, Korea. p 7 -24.).

As a result of intensive research efforts to develop a novel use of the apple mango extract, the inventors of the present invention have shown that the apple mango extract is not only non-cytotoxic, but also promotes the differentiation and migration of melanoblast cells to be usefully used in the treatment of vitiligo or alopecia. It was confirmed that the present invention was completed.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating vitiligo or leukoplakia comprising an apple mango ( Mangifera indica L. ) extract as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for preventing or improving vitiligo or leukoplakia comprising an apple mango extract as an active ingredient.

Another object of the present invention is to provide a skin external preparation for preventing or improving vitiligo or leukoplakia comprising an apple mango extract as an active ingredient.

Another object of the present invention is to provide a health functional food for preventing or improving vitiligo or alopecia, including apple mango extract as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating vitiligo or leukoplakia comprising an apple mango ( Mangifera indica L. ) extract as an active ingredient.

In addition, the present invention provides a cosmetic composition for preventing or improving vitiligo or alopecia, comprising an apple mango ( Mangifera indica L. ) extract as an active ingredient.

In addition, the present invention provides a skin external preparation for preventing or improving vitiligo or leukoplakia comprising an apple mango ( Mangifera indica L. ) extract as an active ingredient.

In addition, the present invention provides a health functional food for preventing or improving vitiligo or alopecia, including apple mango ( Mangifera indica L. ) extract as an active ingredient.

The apple mango extract of the present invention not only has no cytotoxicity, but also promotes the differentiation and migration of melanoblast cells, so it can be usefully used in the treatment of vitiligo or alopecia.

1 is a diagram showing the appearance of apple mango ( Mangifera indica L. ).
Figure 2 is a result showing the cell viability of melanoblast (Melb-a) treated with apple mango extract (Neg control (negative control): DMSO treatment).
3 is a result of measuring the melanin content of melanoblast (Melb-a) treated with apple mango extract (Neg control (negative control): DMSO treatment).
Figure 4 is a diagram showing the appearance of melanoblast (Melb-a) cells passing through the membrane after the apple mango extract treatment (Neg control (negative control): DMSO treatment).
Figure 5 is a result of counting the number of melanoblast (Melb-a) cells passed through the membrane after the apple mango extract treatment (Neg control (negative control): DMSO treatment).

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for preventing or treating vitiligo or leukoplakia comprising an apple mango ( Mangifera indica L. ) extract as an active ingredient.

The apple mango extract can be prepared by a manufacturing method comprising the following steps:

1) extracting apple mango by adding an extraction solvent;

2) filtering the extract of step 1); And

3) A step of drying after concentrating the filtered extract of step 2) under reduced pressure.

In the above method, the apple mango in step 1) can be used without limitation, such as grown or commercially available.

In the above manufacturing method, apple mango may be used by purchasing dried apple mango made in Taiwan, but is not limited thereto.

In addition, the extraction solvent of step 1) may be water, a lower alcohol of C ₁ to C ₂ , or a mixed solvent thereof, and specifically, the lower alcohol of C ₁ to C ₂ may be methanol or ethanol. According to a specific embodiment of the present invention, it is most preferable to extract with methanol.

The extraction method of step 1) may be shaking extraction, Soxhlet extraction, or reflux extraction. At this time, the extraction temperature is preferably 20 to 60 ℃, more preferably 30 to 50 ℃, but is not limited thereto. In addition, the extraction solvent is preferably extracted by adding 2 to 10 times the weight of the apple mango used for extraction, and it is more preferable to extract by adding 4 to 8 times, but is not limited thereto.

In addition, the extraction time is preferably 10 to 40 hours, more preferably 20 to 30 hours, but is not limited thereto. In addition, the number of extractions is preferably 1 to 5 times, more preferably 1 to 3 times, but is not limited thereto. The content of the active ingredient in the apple mango extract may be insignificant because extraction is not sufficiently performed in a range outside the conditions of the extraction temperature, extraction time, or extraction frequency. Alternatively, the extraction yield may no longer increase, so that the efficiency of the extraction operation may decrease.

The vacuum concentration in step 3) may be performed using a vacuum vacuum concentrator or a vacuum rotary evaporator. In addition, the drying may be vacuum drying, vacuum drying, boiling drying, spray drying, or freeze drying.

The extract may induce the differentiation of melanoblast into melanocytes. In addition, the extract can promote the movement of melanoblast.

In a specific embodiment of the present invention, the present inventors purchased dried apple mango from Taiwan and then extracted with methanol to prepare an apple mango extract, and the apple mango extract did not show cytotoxicity in melanoblast, as well as (see FIG. 2 ). ) It was confirmed that the melanin content and differentiation of melanoblast were induced (see FIG. 3), and the movement of melanoblast was promoted (see FIGS. 4 to 5).

Therefore, the apple mango extract of the present invention can be usefully used in a pharmaceutical composition for preventing or treating vitiligo or alopecia.

The pharmaceutical composition according to the present invention may contain 10 to 95% by weight of an active ingredient, apple mango extract, based on the total weight of the composition. In addition, the pharmaceutical composition of the present invention may further include one or more active ingredients exhibiting the same or similar functions in addition to the active ingredients.

The pharmaceutical composition of the present invention may contain a carrier, a diluent, an excipient, or a mixture thereof commonly used in biological preparations. Any pharmaceutically acceptable carrier can be used as long as it is suitable for delivering the composition in vivo. Specifically, the carrier is Merck Index, 13th ed., Merck & Co. Inc., saline, sterile water, Ringer's solution, dextrose solution, maltodextrin solution, glycerol, ethanol, or a mixture thereof. In addition, conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed.

When formulating the composition, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants may be added.

The composition of the present invention may be formulated as an oral or parenteral formulation. Oral formulations may include solid formulations and liquid formulations. The solid preparation may be a tablet, a pill, a powder, a granule, a capsule, or a troche, and the solid preparation may be prepared by adding at least one excipient to the composition. The excipient may be starch, calcium carbonate, sucrose, lactose, gelatin, or a mixture thereof. In addition, the solid preparation may contain a lubricant, examples of which include magnesium stearate and talc. On the other hand, the liquid formulation may be a suspension, an inner solution, an emulsion or a syrup. In this case, the liquid formulation may contain excipients such as wetting agents, sweetening agents, fragrances, and preservatives.

The parenteral preparations may include injections, suppositories, powders for respiratory inhalation, aerosols for sprays, powders and creams. The injection may include a sterilized aqueous solution, a non-aqueous solvent, a suspension solvent, an emulsion, and the like. At this time, as the non-aqueous solvent or suspension solvent, vegetable oils such as propylene glycol, polyethylene glycol, and olive oil, or injectable esters such as ethyl oleate may be used.

The composition of the present invention may be administered orally or parenterally according to a desired method. Parenteral administration may include intraperitoneal, rectal, subcutaneous, intravenous, intramuscular or intrathoracic injection.

The composition may be administered in a pharmaceutically effective amount. This may vary depending on the type of disease, the severity, the activity of the drug, the patient's sensitivity to the drug, the administration time, the administration route, the treatment period, and the drugs used at the same time. However, for a desirable effect, the amount of the active ingredient contained in the pharmaceutical composition according to the present invention may be 0.0001 to 1,000 mg/kg, specifically 0.001 to 500 mg/kg. The administration may be several times a day.

The composition of the present invention may be administered alone or in combination with other therapeutic agents. When administered in combination, administration may be sequential or simultaneous.

In addition, the present invention provides a cosmetic composition for preventing or improving vitiligo or leukoplakia comprising an apple mango extract as an active ingredient.

The characteristics of the apple mango extract according to the present invention are as described above. For example, the apple mango extract may be extracted with water, C ₁ to C ₂ lower alcohol or a mixed solvent thereof, and specifically, the C ₁ to C ₂ lower alcohol may be methanol or ethanol. The extract may induce the differentiation of melanoblast into melanocytes. In addition, the extract can promote the movement of melanoblast.

In a specific embodiment of the present invention, the present inventors purchased Taiwan-made dried apple mango, and extracted it with methanol to prepare an apple mango extract, and the apple mango extract did not show cytotoxicity in melanoblast (Fig. 2). See) It was confirmed that melanin content and differentiation of melanoblast are induced (see FIG. 3), and movement of melanoblast is promoted (see FIGS. 4 to 5).

Therefore, the apple mango extract of the present invention can be usefully used in a cosmetic composition for preventing or improving vitiligo or alopecia.

The composition of the present invention may further include one or more active ingredients exhibiting the same or similar function to the extract.

In addition, specific formulations of the cosmetic composition of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, nutrition essence, It includes formulations such as packs, soaps, shampoos, cleansing foams, cleansing lotions, cleansing creams, body lotions, body cleansers, emulsions, press powders, loose powders, and eye shadows.

In addition, the cosmetic composition may include fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, forming agents, fragrances, surfactants, in addition to the mixed extract of the present invention. Water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic activators, lipid vesicles or commonly used in cosmetics It may contain adjuvants commonly used in the cosmetic field, such as any other ingredients that are used.

In the composition of the present invention, the extract is preferably contained in an amount of 0.005 to 90% by weight based on the total weight of the composition, but it has an effect of preventing or improving vitiligo or alopecia and does not show toxicity. Can also be used.

In addition, the present invention provides a skin external preparation for preventing or improving vitiligo or leukoplakia comprising an apple mango extract as an active ingredient.

Apple mango extract according to the present invention is as described above. For example, the apple mango extract may be extracted with water, C ₁ to C ₂ lower alcohol or a mixed solvent thereof, and specifically, the C ₁ to C ₂ lower alcohol may be methanol or ethanol. The extract may induce the differentiation of melanoblast into melanocytes. In addition, the extract can promote the movement of melanoblast.

When using the extract as an external preparation for skin, additionally fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, forming agents, fragrances, surfactants, water, Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic activators, lipid vesicles or any commonly used in cosmetics It may contain adjuvants commonly used in the cosmetic field, such as other ingredients of. In addition, the ingredients may be introduced in an amount generally used in the field of dermatology.

In addition, the present invention provides a health functional food for preventing or improving vitiligo or alopecia, including apple mango extract as an active ingredient.

Apple mango extract according to the present invention is as described above. For example, the apple mango extract may be extracted with water, C ₁ to C ₂ lower alcohol or a mixed solvent thereof, and specifically, the C ₁ to C ₂ lower alcohol may be methanol or ethanol. The extract may induce the differentiation of melanoblast into melanocytes. In addition, the extract can promote the movement of melanoblast.

The term "health functional food" as used herein refers to a food manufactured using nutrients that are easily deficient in daily meals or raw materials or ingredients having useful functions for the human body, and refers to foods that help maintain human health, but is not limited thereto. It is used as a meaning that includes all health foods in the usual meaning.

The form and type of the health functional food is not particularly limited. Specifically, the health functional food may be in the form of tablets, capsules, powders, granules, liquids, and pills. The health functional food may contain various flavoring agents, sweetening agents, or natural carbohydrates as additional ingredients. The sweetener may be a natural or synthetic sweetener, and examples of the natural sweetener include taumatin and stevia extract. Meanwhile, examples of synthetic sweeteners include saccharin and aspartame. In addition, the natural carbohydrates may be monosaccharides, disaccharides, polysaccharides, oligosaccharides and sugar alcohols.

In addition to the above-described additional ingredients, the health functional food of the present invention includes nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pexane and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives. , Glycerin, alcohol, and the like may be further included. These ingredients can be used independently or in combination. The proportion of the additive may be selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

The apple mango extract of the present invention may be added to food as it is or used with other foods or food ingredients. At this time, the content of the added active ingredient may be determined according to the purpose. In general, the content of the health functional food may be 0.01 to 90 parts by weight of the total food weight. However, in the case of long-term intake for the purpose of health and hygiene or for health control purposes, the amount may be less than the above range, and if there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.

Hereinafter, the present invention will be described in detail by the following examples.

However, the following examples are only illustrative of the present invention, and the contents of the present invention are not limited by the following examples.

<Example 1> Preparation of apple mango extract

Taiwan-made dried apple mango ( Mangifera indica L. ) was purchased and used. Five times the amount of methanol compared to the apple mango sample was added and extracted at 40° C. for 24 hours. After performing the extraction process twice, the extract was filtered using a filter paper (Whatman filter paper No. 1) and then reduced pressure to obtain a methanol extract of apple mango as a concentrate.

<Example 2> Melanoblast cell line culture

Melanoblast (Melb-a) was pre-sold and used from Functional Genomics Cell Bank (UK), Welcome Trust. Melb-a is in complete RPMI1640 medium (RPMI 1640 medium (Invitrogen Corp (USA)) in 1% penicillin/streptomycin, 1 ng/ml bFGF (Murine Fibroblast growth factor (FGF)-basic; PeproTech) , 20 nM PDBu (Phorbol12,13-dibutyrate; Sigma Chemical Co, USA), and 5% fetal bovine serum (added with Fetal bovine serum; Invitrogen Corp, USA) at 37° C., 10% CO ₂ passage in an incubator Cultured. In the subculture, trypsin-EDTA (trypsin-EDTA; Invitrogen Corp (USA)) was treated with the cultured cells and precipitated by centrifugation, the supernatant was removed, and complete RPMI 1640 medium was added to suspend the cells. It was carried out by redistributing in a 10 cm cell culture dish at a concentration of x 10 ⁴ cells/dish.

<Experimental Example 1> Confirmation of the effect of apple mango extract on the survival rate of melanoblast cells

6×10 ⁴ melanoblast cells were inoculated into a 12-well plate, pre-cultured for 24 hours in a 37°C, 10% CO ₂ incubator, and then the culture medium was removed and the dried apple mango of Example 1 dissolved in DMSO ( Mangifera indica L. ) The culture solution containing the extract was treated at concentrations of 10 and 50 μg/ml, respectively. DMSO was treated as a negative control, and α-MSH (alpha-melanocyte stimulating hormone) was treated as a positive control. After treatment with the apple mango extract, the medium was changed every two days for 4 days, and the apple mango extract was treated again when the medium was changed. After treatment with the MTT reagent (5 mg/ml) on the cells cultured on the 4th day from the first treatment with the apple mango extract, the formed formazan was dissolved in DMSO, and 540 nm using an ELISA microplate reader. The absorbance of the wavelength was measured and compared with the untreated control group.

As a result, it was confirmed that the apple mango extract did not show toxicity in melanoblast cells when treated at a concentration of 10-50 μg/ml (FIG. 2).

<Experimental Example 2> Confirmation of the effect of apple mango extract on melanoblast differentiation

Melanoblast is a non-pigmented cell in which the catalytic function of tyrosinase is stopped. In order to confirm whether the apple mango extract induces the differentiation of melanoblast, the melanin content of melanoblast was measured.

<Melanin content measurement>

6×10 ⁴ melanoblast cells were inoculated into a 12-well plate, pre-cultured for 24 hours in a 37°C, 10% CO ₂ incubator, and then the culture medium was removed and the dried apple mango of Example 1 dissolved in DMSO ( Mangifera indica L. ) The culture solution containing the extract was treated at concentrations of 10, 25, 50, and 100 μg/ml, respectively. DMSO was treated as a negative control, and α-MSH was treated as a positive control. After treatment with the apple mango extract, the medium was changed every two days for 4 days, and the apple mango extract was treated again when the medium was changed. The culture medium of the cells cultured on the 4th day from the time point when the apple mango extract was first treated was removed, washed twice with 500 µl of PBS, and then treated with trypsin-EDTA to obtain cells. The obtained cells were transferred to a 1.5 ml microtube, centrifuged to precipitate the cells, and the supernatant was removed, and then suspended in 100 μl of a 1N NaOH solution containing 10% DMSO and reacted at 80° C. for 1 hour. The melanin in the lysed cells was measured for absorbance at a wavelength of 405 nm using a plate reader and compared with the untreated control group.

As a result of visual observation of the melanoblast precipitate, the negative control was white, whereas the positive control (α-MSH) and the experimental group treated with apple mango extract showed a color change, indicating that melanin synthesis was induced. As a result of measuring the melanin content, the experimental group treated with the apple mango extract showed an increase in melanin content (50 ppm apple mango extract: 112%), which was similar to the positive control (114%) (FIG. 3). The above results show that the apple mango extract induced the differentiation of melanoblast into melanocytes.

<Experimental Example 3> Confirmation of the effect of apple mango extract on melanoblast migration

Melanocytes differentiated from melanoblast migrate to epidermal tissue, and then transfer the produced melanin to keratinocytes to color the skin. Therefore, the following experiment was performed to confirm whether the apple mango extract induces the migration of melanoblast cells.

Specifically, cell migration was measured using a transwell cell culture chamber (ostar 3422). A 0.8 μm polyvinylpyrroliodone-free polycarbonate filter in a transwell cell culture chamber was coated with 1% gelatin. After the coated filter was hardened, 600 µl of serum-free RPMI medium containing the apple mango extract of Example 1 was added to the lower part of the chamber, and melanoblast cells (2.5 × 10 ⁵ cells/ml) were added to the upper part of the chamber. Was inoculated with 100 μl and incubated for 24 hours. When the culture was completed, the filter was cut out, fixed with methanol, stained with hematoxylin and eosin, and then cells that had not migrated on the filter were removed using a cotton swab. The cells moved to the lower part of the filter were observed under a microscope, and the filter was divided into quarters and then enlarged 40 times under a microscope to measure the number of cells and calculate the average value. The experiment was repeated twice under each condition.

As a result, it was found that the number of melanoblast cells increased by 146% and 162%, respectively, compared to the untreated control, on the lower side of the filter treated with the apple mango extract at concentrations of 10 and 50 ppm. It was confirmed that it was promoted (FIGS. 4 and 5).

Claims (8)

A pharmaceutical composition for preventing or treating vitiligo or leukoplakia comprising apple mango extract as an active ingredient.
The method of claim 1,
The apple mango extract is extracted with water, C ₁ to C ₂ of lower alcohol or a mixed solvent thereof, a pharmaceutical composition for preventing or treating vitiligo or alopecia.
The method of claim 2,
The lower alcohol of the C ₁ to C ₂ is methanol or ethanol, a pharmaceutical composition for preventing or treating vitiligo or alopecia.
The method of claim 1,
The extract is a pharmaceutical composition for preventing or treating vitiligo or alopecia, which induces the differentiation of melanoblast into melanocytes.
The method of claim 1,
The extract is a pharmaceutical composition for the prevention or treatment of vitiligo or alopecia to promote the movement of melanoblast.
A cosmetic composition for preventing or improving vitiligo or leukoplakia comprising apple mango extract as an active ingredient.
Skin external preparation for preventing or improving vitiligo or leukoplakia comprising apple mango extract as an active ingredient.
Health functional food for preventing or improving vitiligo or leukoplakia containing apple mango extract as an active ingredient.

Images